Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19908066)

  • 1. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
    Artac M; Bozcuk H; Pehlivan S; Akcan S; Pehlivan M; Sever T; Ozdogan M; Savas B
    J Cancer Res Clin Oncol; 2010 Jun; 136(6):803-9. PubMed ID: 19908066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.
    Gan Y; Li XR; Chen DJ; Wu JH
    Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
    Li Y; Huang XE; Jin GF; Shen HB; Xu L
    Asian Pac J Cancer Prev; 2011; 12(3):739-42. PubMed ID: 21627375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.
    Sreeja L; Syamala VS; Syamala V; Hariharan S; Raveendran PB; Vijayalekshmi RV; Madhavan J; Ankathil R
    J Cancer Res Clin Oncol; 2008 Jun; 134(6):645-52. PubMed ID: 17952468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
    Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
    Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pterygium and genetic polymorphisms of the DNA repair enzymes XRCC1, XPA, and XPD.
    Chiang CC; Tsai YY; Bau DT; Cheng YW; Tseng SH; Wang RF; Tsai FJ
    Mol Vis; 2010 Apr; 16():698-704. PubMed ID: 20431719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
    Crea F; Fornaro L; Paolicchi E; Masi G; Frumento P; Loupakis F; Salvatore L; Cremolini C; Schirripa M; Graziano F; Ronzoni M; Ricci V; Farrar WL; Falcone A; Danesi R
    Ann Oncol; 2012 May; 23(5):1207-1213. PubMed ID: 21926398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
    Kim DY; Paek TY; Oh SY; Kim YB; Lee JH; Lee MY; Choi ZS; Suh KW
    J Surg Oncol; 2014 Mar; 109(3):250-4. PubMed ID: 24318863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
    Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
    Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients.
    Castro E; Olmos D; Garcia A; Cruz JJ; González-Sarmiento R
    Clin Transl Oncol; 2014 Feb; 16(2):158-65. PubMed ID: 23740134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associated risk of XRCC1 and XPD cross talk and life style factors in progression of head and neck cancer in north Indian population.
    Kumar A; Pant MC; Singh HS; Khandelwal S
    Mutat Res; 2012 Jan; 729(1-2):24-34. PubMed ID: 21945240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population.
    Chen S; Tang D; Xue K; Xu L; Ma G; Hsu Y; Cho SS
    Carcinogenesis; 2002 Aug; 23(8):1321-5. PubMed ID: 12151350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of DNA repair genes XPD and XRCC1 and risk of cataract development.
    Unal M; Güven M; Batar B; Ozaydin A; Sarici A; Devranoğlu K
    Exp Eye Res; 2007 Sep; 85(3):328-34. PubMed ID: 17637462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of DNA repair genes polymorphism (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients.
    Hussien YM; Gharib AF; Awad HA; Karam RA; Elsawy WH
    Mol Biol Rep; 2012 Feb; 39(2):1895-901. PubMed ID: 21643959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of the DNA repair genes XPD and XRCC1 and the risk of age-related macular degeneration.
    Görgün E; Güven M; Unal M; Batar B; Güven GS; Yenerel M; Tatlipinar S; Seven M; Yüksel A
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4732-7. PubMed ID: 20375340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in two DNA repair genes (XPD and XRCC1)--association with age related cataracts.
    Padma G; Mamata M; Reddy KR; Padma T
    Mol Vis; 2011 Jan; 17():127-33. PubMed ID: 21245954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of XPD Asp312Asn polymorphism and response to oxaliplatin-based first-line chemotherapy and survival in patients with metastatic colorectal cancer.
    Liu Z; Kong J; Kong Y; Cai F; Xu X; Liu J; Wang S
    Adv Clin Exp Med; 2019 Nov; 28(11):1459-1468. PubMed ID: 31756062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
    Huang L; Zhang T; Xie C; Liao X; Yu Q; Feng J; Ma H; Dai J; Li M; Chen J; Zang A; Wang Q; Ge S; Qin K; Cai J; Yuan X
    PLoS One; 2013; 8(10):e77223. PubMed ID: 24143213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.